logo-loader
viewValiRx PLC

Appointment of Joint Broker

/**/ p{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}link{ color: blue }visited{ color: #954F72 } .p{size:595.0pt 842.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.p{}p.bc{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right:59.25pt;line-height:150%}span.ba{font-size:10.0pt;line-height:150%;font-family:"Calibri","sans-serif"}p.bd{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 150%; margin-right: 59.25pt}span.ay{font-size:10.0pt;line-height:150%}p.be{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 150%; margin-right: 59.25pt; text-align: center}span.aw{font-size:10.0pt; line-height:150%}p.bf{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: 150%; margin-right: 59.25pt; text-align: center}span.au{font-size:10.0pt;line-height: 150%} span.as{font-size:10.0pt; line-height:150%;letter-spacing:.1pt}p.bg{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 150%; text-align: justify; text-autospace: none}p.bh{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify;line-height:150%}span.aq{letter-spacing:.05pt}span.ap{font-size:10.0pt; line-height:150%;font-family:"Calibri","sans-serif";letter-spacing:.05pt}span.an{font-size:10.0pt;line-height:150%;font-family:"Calibri","sans-serif"; letter-spacing:.05pt}p.bi{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 150%; text-align: justify}p.bj{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; line-height: 150%; text-align: justify}p.aj{ font-weight: bold; line-height: 150%}span.ak{font-size:10.0pt; line-height:150%;font-family:"Calibri","sans-serif"} p.ai{ font-weight: bold; line-height: 150%; text-align: center}p.ah{line-height:150%;background:white}p.bk{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 150%}p.bl{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;font-weight: bold; line-height: 150%}span.af{font-size:10.0pt; line-height:150%;font-family:"Calibri","sans-serif";color:windowtext}table.bm{margin-left:-5.4pt;border-collapse:collapse}td.ad{width:260.7pt;padding:0cm 5.4pt 0cm 5.4pt}p.bn{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 150%; margin: 0cm; margin-bottom: .0001pt}td.ab{width:168.2pt;padding:0cm 5.4pt 0cm 5.4pt}p.bo{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;line-height:150%} span.bp{font-family: "Calibri","sans-serif"; font-size: 10.0pt; font-weight: bold; line-height: 150%}span.z{font-size:5.0pt;line-height:150%;font-family:"Calibri","sans-serif"}p.bq{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 150%; margin-bottom: 10.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 0cm}span.y{font-size:5.0pt; line-height:150%;font-family:"Calibri","sans-serif"}p.br{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt; margin-left:0cm;line-height:150%}p.bs{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold}span.u{font-size:10.0pt;font-family:"Calibri","sans-serif"}br.s{page-break-before:always}span.r{text-transform: uppercase}p.bt{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:8.0pt;font-family:"LyonText-Semibold","serif";color:black;text-align:justify;line-height:150%} span.q{font-size:10.0pt;line-height:150%;font-family:"Calibri","sans-serif"; color:windowtext} /**/
RNS Number : 3195G
ValiRx PLC
23 July 2019
 

 

 

 

VALIRX PLC

("ValiRx" or the "Company")

 

APPOINTMENT OF JOINT BROKER

 

London, UK., 23 July 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces the appointment of SVS Securities PLC as the Company's joint broker.

 

Dr Satu Vainikka, CEO of ValiRx Plc, commented:

"I look forward to working with the team at SVS and the Company benefiting from the broker's life-science research capabilities to promote and facilitate understanding and transparency regarding the progress of our clinical trials".

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc

Tel: +44 (0) 20 3008 4416

www.valirx.com

Dr Satu Vainikka, Chief Executive

Tel: +44 (0) 20 3008 4416

Tarquin Edwards, Head of Communications.

Tel: +44 (0) 7879 458 364

[email protected]



Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: +44 (0) 20 7213 0880



SVS Securities PLC (Joint Broker)

Elliot Hance

Tel: +44 (0) 20 3700 0093



Novum Securities Limited (Joint Broker)

Colin Rowbury

Tel: +44 (0) 20 7399 9400

 



 

 

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

 

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

 

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College. 

 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
APPPGUWGMUPBGCP

Quick facts: ValiRx PLC

Price: 0.1323

Market: AIM
Market Cap: £1.35 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

RNS

Passing of Non-Executive Chairman

1 day, 23 hours ago

Placing & Issue of Equity

1 week, 2 days ago

Half-year Report

3 weeks, 6 days ago

Company Update

4 weeks, 1 day ago

VAL201 Update

on 10/9/19